1543 related articles for article (PubMed ID: 19376687)
21. Thymol inhibits Candida albicans biofilm formation and mature biofilm.
Braga PC; Culici M; Alfieri M; Dal Sasso M
Int J Antimicrob Agents; 2008 May; 31(5):472-7. PubMed ID: 18329858
[TBL] [Abstract][Full Text] [Related]
22. Transcription factor Efg1 contributes to the tolerance of Candida albicans biofilms against antifungal agents in vitro and in vivo.
Bink A; Govaert G; Vandenbosch D; Kuchariková S; Coenye T; Nelis H; Van Dijck P; Cammue BPA; Thevissen K
J Med Microbiol; 2012 Jun; 61(Pt 6):813-819. PubMed ID: 22422573
[TBL] [Abstract][Full Text] [Related]
23. In vitro method to study antifungal perfusion in Candida biofilms.
Samaranayake YH; Ye J; Yau JY; Cheung BP; Samaranayake LP
J Clin Microbiol; 2005 Feb; 43(2):818-25. PubMed ID: 15695686
[TBL] [Abstract][Full Text] [Related]
24. Quinacrine inhibits Candida albicans growth and filamentation at neutral pH.
Kulkarny VV; Chavez-Dozal A; Rane HS; Jahng M; Bernardo SM; Parra KJ; Lee SA
Antimicrob Agents Chemother; 2014 Dec; 58(12):7501-9. PubMed ID: 25288082
[TBL] [Abstract][Full Text] [Related]
25. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans.
Ramage G; VandeWalle K; López-Ribot JL; Wickes BL
FEMS Microbiol Lett; 2002 Aug; 214(1):95-100. PubMed ID: 12204378
[TBL] [Abstract][Full Text] [Related]
26. The Candida albicans Ddr48 protein is essential for filamentation, stress response, and confers partial antifungal drug resistance.
Dib L; Hayek P; Sadek H; Beyrouthy B; Khalaf RA
Med Sci Monit; 2008 Jun; 14(6):BR113-121. PubMed ID: 18509269
[TBL] [Abstract][Full Text] [Related]
27. Inhibitory Effect of Sophorolipid on Candida albicans Biofilm Formation and Hyphal Growth.
Haque F; Alfatah M; Ganesan K; Bhattacharyya MS
Sci Rep; 2016 Mar; 6():23575. PubMed ID: 27030404
[TBL] [Abstract][Full Text] [Related]
28. Thymus vulgaris essential oil and thymol inhibit biofilms and interact synergistically with antifungal drugs against drug resistant strains of Candida albicans and Candida tropicalis.
Jafri H; Ahmad I
J Mycol Med; 2020 Apr; 30(1):100911. PubMed ID: 32008964
[TBL] [Abstract][Full Text] [Related]
29. Inhibition of Candida albicans biofilm formation and yeast-hyphal transition by 4-hydroxycordoin.
Messier C; Epifano F; Genovese S; Grenier D
Phytomedicine; 2011 Mar; 18(5):380-3. PubMed ID: 21353508
[TBL] [Abstract][Full Text] [Related]
30. Susceptibility of Candida albicans biofilms grown in a constant depth film fermentor to chlorhexidine, fluconazole and miconazole: a longitudinal study.
Lamfon H; Porter SR; McCullough M; Pratten J
J Antimicrob Chemother; 2004 Feb; 53(2):383-5. PubMed ID: 14729749
[TBL] [Abstract][Full Text] [Related]
31. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofilm production.
Tortorano AM; Prigitano A; Biraghi E; Viviani MA;
J Antimicrob Chemother; 2005 Oct; 56(4):777-9. PubMed ID: 16144871
[TBL] [Abstract][Full Text] [Related]
32. Non-lethal Candida albicans cph1/cph1 efg1/efg1 mutant partially protects mice from systemic infections by lethal wild-type cells.
Yang YL; Wang CW; Chen CT; Wang MH; Hsiao CF; Lo HJ
Mycol Res; 2009 Mar; 113(Pt 3):388-90. PubMed ID: 19111931
[TBL] [Abstract][Full Text] [Related]
33. Phosphatidylinositol 3-kinase VPS34 of Candida albicans is involved in filamentous growth, secretion of aspartic proteases, and intracellular detoxification.
Kitanovic A; Nguyen M; Vogl G; Hartmann A; Günther J; Würzner R; Künkel W; Wölfl S; Eck R
FEMS Yeast Res; 2005 Feb; 5(4-5):431-9. PubMed ID: 15691748
[TBL] [Abstract][Full Text] [Related]
34. Biofilm inhibition by Cymbopogon citratus and Syzygium aromaticum essential oils in the strains of Candida albicans.
Khan MS; Ahmad I
J Ethnopharmacol; 2012 Mar; 140(2):416-23. PubMed ID: 22326355
[TBL] [Abstract][Full Text] [Related]
35. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species.
Chamilos G; Lionakis MS; Lewis RE; Lopez-Ribot JL; Saville SP; Albert ND; Halder G; Kontoyiannis DP
J Infect Dis; 2006 Apr; 193(7):1014-22. PubMed ID: 16518764
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of Candida albicans biofilm formation on denture material.
Redding S; Bhatt B; Rawls HR; Siegel G; Scott K; Lopez-Ribot J
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 May; 107(5):669-72. PubMed ID: 19426921
[TBL] [Abstract][Full Text] [Related]
37. The inhibitory effects of aureobasidin A on Candida planktonic and biofilm cells.
Tan HW; Tay ST
Mycoses; 2013 Mar; 56(2):150-6. PubMed ID: 22882276
[TBL] [Abstract][Full Text] [Related]
38. Effects of magnolol and honokiol on adhesion, yeast-hyphal transition, and formation of biofilm by Candida albicans.
Sun L; Liao K; Wang D
PLoS One; 2015; 10(2):e0117695. PubMed ID: 25710475
[TBL] [Abstract][Full Text] [Related]
39. The possible molecular mechanisms of farnesol on the antifungal resistance of C. albicans biofilms: the regulation of CYR1 and PDE2.
Chen S; Xia J; Li C; Zuo L; Wei X
BMC Microbiol; 2018 Dec; 18(1):203. PubMed ID: 30509171
[TBL] [Abstract][Full Text] [Related]
40. Serum repressing efflux pump CDR1 in Candida albicans.
Yang YL; Lin YH; Tsao MY; Chen CG; Shih HI; Fan JC; Wang JS; Lo HJ
BMC Mol Biol; 2006 Jul; 7():22. PubMed ID: 16839415
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
